Two doses of a simple tuberculosis vaccine after surgery support the immune system in fighting cancer cells and could significantly improve treatment outcomes for the most common form of bladder cancer, according to a pilot study involving 40 patients. Initial results of the RUTIVAC-1 study were presented at EAU25.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Management of patients after alloHCST
ERS/EBMT guideline recommendations on pulmonary cGvHD
- Pyoderma gangraenosum
New study data confirm the validity of the PARACELSUS score
- Progressive multiple sclerosis
New horizons: from BTK inhibitors to remyelination
- Cutaneous and especially facial metastases
Rare manifestations of esophageal carcinoma
- Rare pulmonary syndromes
Yellow nail and Swyer-James syndrome
- IMCAS Refresher: Aging Sciences/Plastic Surgery
Trends in aesthetic and regenerative medicine
- Pelargonium sidoides
Scoping review sheds light on the multifaceted spectrum of effects
- New evidence on genetics, pathophysiology and clinical significance